表紙
市場調査レポート

好中球減少症:治療薬パイプライン分析および2016年までの市場予測

Neutropenia - Drug Pipeline Analysis and Market Forecasts to 2016

発行 GlobalData 商品コード 121503
出版日 ページ情報 英文 39 Pages
即納可能
価格
こちらの商品の販売は終了いたしました。
Back to Top
好中球減少症:治療薬パイプライン分析および2016年までの市場予測 Neutropenia - Drug Pipeline Analysis and Market Forecasts to 2016
出版日: 2010年05月14日 ページ情報: 英文 39 Pages

当商品の販売は、2016年07月01日を持ちまして終了しました。

概要

当レポートでは、好中球減少症市場について治療薬パイプライン分析および2016年までの市場予測を行っており、市場の特徴をはじめ、競合、パイプラインなどを評価分析し、将来の市場競争、企業プロファイルを盛り込んで、概略以下の構成でお届けします。

第1章 目次

第2章 好中球減少症市場:市場の特徴

  • 市場概要
  • 市場規模
  • 市場予測および年複利成長率(CAGR)
  • 市場促進要因
  • 市場阻害要因
  • 機会およびアンメットニーズ

第3章 競合のアセスメント

  • 概要
  • 戦略的競合企業の評価
  • 主な市販製品のプロファイル
  • オフラベル医薬品の製品プロファイル
  • 要点

第4章 パイプラインのアセスメント

  • 概要
  • 戦略的パイプラインの評価
  • 臨床開発中の有望なパイプラインの分子プロファイル
  • 好中球減少症:作用機序別臨床パイプライン
  • 好中球減少症パイプライン:臨床開発段階別パイプライン
  • 要点

第5章 将来の市場競争についての示唆

第6章 将来の企業

  • イントロダクション
  • Maxygen
  • Pfizer 27
  • Teva Pharmaceutical Industries Limited

第7章 付録

図表

目次
Product Code: GDHCPRT090

Abstract

Neutropenia - Drug Pipeline Analysis and Market Forecasts to 2016

Summary

GlobalData' s pharmaceutical and healthcare report offering, “Neutropenia - Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global lung cancer market. This pharma report identifies the key trends shaping and driving the global neutropenia market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global neutropenia sector.

GlobalData estimated the global neutropenia market to grow by 4% annually for the next seven years to reach $8.6 billion in 2016. This moderate growth is primarily attributed to the increase in the uptake of biologics and the presence of strong pipeline candidates. The growth will be supported by increases in incidence and prevalence of the disease, and the high prescription rate of the currently marketed products. GlobalData determined that the global neutropenia market is moderately served by the current product options and significant scope is available to new entrants that can capture value from underserved segments. Designing highly efficacious products that will encourage physician compliance is one of key challenges of this market and could provide a significant market share for any company achieving this.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:
- Annualized global neutropenia market revenues data from 2001 to 2009, forecast for seven years to 2016.
- The geographies covered in this report are the United States (US), the Untied Kingdom (UK), Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. The key classes of mechanism of action include D-alanyl-D-alanine binders, fungal cytochrome P-450 inhibitors, Granulocyte Colony Stimulating Factor (G-CSF) binders and bone marrow stimulators.
- Analysis of the current and future market competition in the global neutropenia market. The key market players covered are Amgen, Pfizer, Maxygen, Teva Pharmaceuticals and CoGenesys (which is now a part of Teva Pharmaceuticals).
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- The key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the future neutropenia market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global neutropenia market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global neutropenia market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global neutropenia market landscape? - Identify, understand and capitalize.

Table of Contents

1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Neutropenia Market: Market Characterization 6
2.1 Market Overview 6
2.2 Neutropenia Market Size 6
2.3 Neutropenia Market forecast and CAGR 7
2.4 Neutropenia Market Drivers 8
2.4.1 Steady Increase in the Prevalence Population 8
2.4.2 Increase in the Uptake of Biologics 9
2.4.3 Increase in the Prescription Population 9
2.4.4 Increase in Conditions Such as Cancer and Cardiovascular Events will Increase the Prevalence of drug induced Neutropenia 9
2.5 Neutropenia Market Restraints 9
2.5.1 Low Diagnosis Rate 9
2.5.2 Patent Expiries of Major Blockbuster Drugs Including Neupogen and Neulasta 10
2.5.3 Opening up of US market to biosimilars and generics 10
2.6 Opportunity and Unmet Need 10
2.6.1 Key Takeaway 11
3 Neutropenia Market: Competitive Assessment 12
3.1 Overview 12
3.2 Strategic Competitor Assessment 12
3.3 Product Profile for the Marketed Drugs for Neutropenia 13
3.3.1 Neulasta (Pegfilgrastim) 13
3.3.2 Neupogen 13
3.4 Product Profile for Off-Label Drugs for Neutropenia 14
3.4.1 Leukine 14
3.5 Key Takeaway 16
4 Neutropenia Market: Pipeline Assessment 17
4.1 Overview 17
4.2 Strategic Pipeline Assessment 17
4.2.1 Technology Trends Analytic Framework 17
4.3 Profile of the Promising Pipeline Molecules in Clinical Development 18
4.3.1 Voriconazole 18
4.3.2 Linezolid 19
4.3.3 Neugranin 19
4.3.4 Maxy-G34 20
4.4 Neutropenia - Clinical Pipeline by Mechanism of Action 20
4.5 Neutropenia Pipeline - Pipeline by Clinical Phases of Development 21
4.5.1 Neutropenia Market - Phase III Clinical Pipeline 22
4.5.2 Neutropenia Market - Phase II Clinical Pipeline 22
4.5.3 Neutropenia Market - Pre Clinical Pipeline 22
4.5.4 Neutropenia Market - Terminated Pipeline Molecules 23
4.5.5 Neutropenia Market - Approved Pipeline Molecules 23
4.6 Key takeaway 23
5 Neutropenia Market: Implications for Future Market Competition 24
6 Neutropenia Market: Future Players in Neutropenia Market 25
6.1 Introduction 25
6.2 Maxygen 25
6.2.1 Company Overview 25
6.2.2 Business Description 26
6.2.3 Hematology Disorder Portfolio 26
6.3 Pfizer 27
6.3.1 Company Overview 27
6.3.2 Financial Performance 28
6.3.3 Business Description 28
6.3.4 Hematology Disorder Portfolio 29
6.4 Teva Pharmaceutical Industries Limited 29
6.4.1 Company Overview 29
6.4.2 Financial Performance 30
6.4.3 Business Description 30
6.4.4 CoGenesys- The company acquired by Teva Pharmceuticals 31
6.4.5 Blood Disorder Portfolio 31
7 Neutropenia Market: Appendix 33
7.1 Definitions 33
7.2 Acronyms 33
7.3 Research Methodology 33
7.3.1 Coverage 34
7.3.2 Secondary Research 34
7.3.3 Forecasting 35
7.3.4 Primary Research 37
7.3.5 Expert Panel Validation 38
7.4 Contact Us 38
7.5 Disclaimer 38
7.6 Sources 38

1.1 List of Tables
Table 1: Neutropenia Market, Revenue ($bn), 2001-2009 7
Table 2: Neutropenia Market, Global, Revenue ($bn), 2009-2016 8
Table 3: Major Marketed Products Comparison in the Neutropenia Market, 2010 15
Table 4: Neutropenia Market- Phase III Clinical Pipeline, 2010 22
Table 5: Neutropenia Market- Phase II Clinical Pipeline, 2010 22
Table 6: Neutropenia Market- Pre Clinical Pipeline, 2010 22
Table 7: Neutropenia Market- Terminated Pipeline Molecules, 2010 23
Table 8: Neutropenia Market- Approved Pipeline Molecules, 2010 23
Table 9: Pfizer Pharmaceuticals- Blood Disorder Marketed Products, 2010 29
Table 10: Pfizer Pharmaceuticals- Blood Disorder Pipeline Products, 2010 29
Table 11: Teva Pharmaceuticals- Blood Disorder Marketed Products, 2010 31
Table 12: Teva Pharmaceuticals- Blood Disorder Pipeline Products, 2010 32

1.2 List of Figures
Figure 1: Neutropenia Market, Global, Revenue ($bn), 2001-2009 7
Figure 2: Neutropenia Market, Global, Revenue ($bn), 2009-2016 8
Figure 3: Opportunity and Unmet Need for Neutropenia Market, 2010 10
Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Neutropenia Market, 2010 12
Figure 5: Technology Trends Analytic Framework of the Neutropenia Pipeline, 2010 17
Figure 6: Technology Trends Analytic Framework of the Neutropenia Pipeline - Description, 2010 18
Figure 7: Neutropenia Market - Clinical Pipeline by Mechanism of Action, 2010 21
Figure 8: Neutropenia Pipeline by Phase of Clinical Development, 2010 21
Figure 9: Implications for Future Market Competition in Neutropenia Market, 2010 24
Figure 10: Neutropenia Market - Clinical Pipeline by Company, 2010 25
Figure 11: GlobalData Methodology, 2010 34
Figure 12: GlobalData Market Forecasting Model, 2010 37

Back to Top